Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13944MR)

This product GTTS-WQ13944MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13944MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1247MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ3435MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ6186MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ9559MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ14433MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ10887MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ13885MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ3618MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW